TY - JOUR
T1 - t(6;14)(p22;q32)
T2 - A new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
AU - Russell, Lisa J.
AU - Akasaka, Takashi
AU - Majid, Aneela
AU - Sugimoto, Kei Ji
AU - Karran, E. Loraine
AU - Nagel, Inga
AU - Harder, Lana
AU - Claviez, Alexander
AU - Gesk, Stefan
AU - Moorman, Anthony V.
AU - Ross, Fiona
AU - Mazzullo, Helen
AU - Strefford, Jonathan C.
AU - Siebert, Reiner
AU - Dyer, Martin J.S.
AU - Harrison, Christine J.
PY - 2008/1/1
Y1 - 2008/1/1
N2 - Translocations involving the immunoglobulin heavy chain locus (IGH@) at chromosome band 14q32 are common in mature B-cell neoplasms, but are rare in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Here, we report the translocation, t(6;14)(p22;q32), involving IGH@ as a novel recurrent translocation in 13 BCP-ALL patients. Fluorescence in situ hybridization and long-distance inverse polymerase chain reaction (PCR) identified ID4 as the partner gene. Breakpoints were scattered over a 19kb region centromeric of ID4. Quantitative real-time PCR showed up-regulation of ID4 mRNA. All patients had deletions of CDKN2A and PAX5 located on the short arm of chromosome 9, frequently as a result of an isochromosome, i(9)(q10) (9/13, 69%). This study defines a new subgroup of BCP-ALL characterized by ID4 overexpression and CDKN2A and PAX5 deletions. Preliminary survival data suggest that this subgroup may be associated with a good response to therapy.
AB - Translocations involving the immunoglobulin heavy chain locus (IGH@) at chromosome band 14q32 are common in mature B-cell neoplasms, but are rare in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Here, we report the translocation, t(6;14)(p22;q32), involving IGH@ as a novel recurrent translocation in 13 BCP-ALL patients. Fluorescence in situ hybridization and long-distance inverse polymerase chain reaction (PCR) identified ID4 as the partner gene. Breakpoints were scattered over a 19kb region centromeric of ID4. Quantitative real-time PCR showed up-regulation of ID4 mRNA. All patients had deletions of CDKN2A and PAX5 located on the short arm of chromosome 9, frequently as a result of an isochromosome, i(9)(q10) (9/13, 69%). This study defines a new subgroup of BCP-ALL characterized by ID4 overexpression and CDKN2A and PAX5 deletions. Preliminary survival data suggest that this subgroup may be associated with a good response to therapy.
UR - http://www.scopus.com/inward/record.url?scp=38049126095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38049126095&partnerID=8YFLogxK
U2 - 10.1182/blood-2007-07-092015
DO - 10.1182/blood-2007-07-092015
M3 - Article
C2 - 17940204
AN - SCOPUS:38049126095
SN - 0006-4971
VL - 111
SP - 387
EP - 391
JO - Blood
JF - Blood
IS - 1
ER -